

			
AETNA BETTER HEALTH® Coverage Policy/Guideline			
Name:	Increlex	Page:	1 of 2
Effective Date:	6/9/2025	Last Review Date:	5/19/2025
Applies to:	<input checked="" type="checkbox"/> Illinois <input checked="" type="checkbox"/> Florida Kids <input checked="" type="checkbox"/> Maryland <input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids <input checked="" type="checkbox"/> Virginia <input checked="" type="checkbox"/> Kentucky PRMD		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Increlex under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no contraindications or exclusions to the prescribed therapy.

FDA-Approved Indications

Increlex is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary insulin-like growth factor-1 (IGF-1) deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Severe primary IGF-1 deficiency is defined by:

- Height standard deviation (SD) score ≤ -3.0 and
- Basal IGF-1 SD score ≤ -3.0 and
- Normal or elevated GH.

Limitations of use: Increlex is not a substitute to GH for approved GH indications. Increlex is not indicated for use in patients with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory corticosteroids.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Increlex

Policy/Guideline:

Documentation:

Submission of the following information is necessary to initiate the prior authorization review:

Initial requests:

- Growth chart
- Pretreatment insulin-like growth factor-1 (IGF-1) level (laboratory report or medical record documentation)*
- Growth hormone provocative test result(s) (laboratory report or medical record documentation)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Increlex

Page: 2 of 2

Effective Date: 6/9/2025

Last Review Date: 5/19/2025

Applies to: ☒ Illinois ☒ Florida Kids ☒ Maryland ☒ New Jersey
☒ Pennsylvania Kids ☒ Virginia ☒ Kentucky PRMD

Continuation of therapy requests:

- Total duration of treatment (approximate duration is acceptable)
- Date of last dose administered
- Approving health plan/pharmacy benefit manager
- Date of prior authorization/approval
- Prior authorization approval letter

* IGF-1 levels vary based on the laboratory performing the analysis. Laboratory-specific values must be provided to determine whether the value is within the normal range.

Criteria for Initial Approval:

Severe Primary IGF-1 Deficiency

Authorization of 12 months may be granted to members with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH when ALL the following criteria are met:

- Pretreatment height is ≥ 3 standard deviations (SD) below the mean for age and gender
- Pretreatment basal IGF-1 level is ≥ 3 SD below the mean for age and gender
- Pediatric GH deficiency has been ruled out with a provocative GH test (i.e., peak GH level ≥ 10 ng/mL)
- Epiphyses are open

Continuation of Therapy:

- Authorization of 12 months may be granted for continuation of therapy for severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH when BOTH the following criteria are met:
- The member's growth rate is > 2 cm/year or there is a documented clinical reason for lack of efficacy (e.g., on treatment less than 1 year, nearing final adult height/late stages of puberty).
- Epiphyses are open (confirmed by X-ray or X-ray is not available).

Approval Duration and Quantity Restrictions:

Approval: 12 months

References:

1. Increlex [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; March 2024.
2. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr*. 2016;86:361-397.
3. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. *Pediatr Clin North Am*. 2011;58:1141-1165.